Loading...
CYTOFLOC: Evaluation of a non-endoscopic immunocytological device (Cytosponge (TM)) for post-chemoradiotherapy surveillance in patients with oesophageal cancer - a feasibility study
Mukherjee, S. O'Connor, H. Harman, R. O'Donovan, M. Debiram-Beecham, I. Alias, B. Bailey, A. Bateman, A. de Caestecker, J. Crosby, T.
Mukherjee, S.
O'Connor, H.
Harman, R.
O'Donovan, M.
Debiram-Beecham, I.
Alias, B.
Bailey, A.
Bateman, A.
de Caestecker, J.
Crosby, T.
Citations
Altmetric:
Abstract
Background: Accurate response assessment in patients with oesophageal cancer
undergoing neo-adjuvant chemoradiotherapy would pave the way for more tailored
management. Cytosponge TM consists of an expandable, spherical mesh attached to
a string and contained within a soluble capsule. The capsule dissolves in the stomach,
releasing the sponge which is retrieved by pulling the string. Oesophageal cells
collected can be evaluated for molecular markers. CYTOFLOC evaluated feasibility,
safety, acceptability and indicative accuracy of Cytosponge TM to assess response in
patients with oesophageal cancer treated with definitive or neoadjuvant chemo radiotherapy (dCRT/nCRT).
Methods: Inclusion: patients 16 years who have undergone dCRT/nCRT, 4-16 weeks
post treatment, dysphagia score 0-2, able to swallow tablets and fit for endoscopy.
Exclusion: varices, strictures, stent. Nurses were trained to administer the Cytosponge
TM. Cytosponge TM was administered after 6 hours fast. Only 2 attempts at swallowing were provided. Acceptance was evaluated through patient questionnaires.
Blood for ctDNA, and corresponding endoscopic/surgical histology assessment was
optional. Primary Objective: Completion rate (The proportion of consented, evaluable, patients successfully undergoing Cytosponge TM). Secondary Objectives: Safety
(all serious adverse events); Suitability of sample for biomarker analysis (Presence of
cytological atypia and/or p53 mutation was considered +ve test); Acceptance rate
(Proportion of eligible patients approached who consented; proportion of patients
who would accept the procedure repeatedly). Tertiary Objectives: detection of ctDNA;
Comparative efficacy of Cytosponge TM to resected/endoscopic histology.
Results: 41 patients were recruited between April 2018 and January 2020 from 11
hospitals. Participant/tumour characteristics: Mean (SD) age 68.32 (10.3) years, median (IQR) baseline tumour length 5cm (2,7). Male:Female (33:8), Dysphagia grade
0:1:2(27:12:2), dCRT:nCRT (28:13), SCC:Adeno (25:16); Site upper:mid:lower:GO
Junction (7:8:22:4). Overall completion rate was 39/41(95.1%, 95% CI 83.5-99.4). 41/
96 (42.7%, 95% CI 32.7,53.2) eligible patients consented, and 37/39 (94.9%, 95% CI
82.7,99.4) were willing to accept repeated procedures. Three grade 1 AE were
recorded (sore throat dysphagia, dyspepsia). 38/39 (97.4%, 95% CI 86.5,99.9) were
considered suitable for biomarker analysis. 9/38 (24%) were considered positive by
cytological criteria. Corresponding histology was available in 33 patients (3 positive on
histology, 30 negative on histology). There was high-level agreement between
negative samples. Of patients with negative histology, 4 patients were atypia positive/
uncertain on Cytosponge TM and 3 were p53 aberrant on Cytosponge TM.
Description
Date
2021
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 124.08 KB
Keywords
Type
Meetings and Proceedings
Citation
Mukherjee S, O’Connor H, Harman R, O’Donovan M, Debiram-Beecham I, Alias B, et al. P-109 CYTOFLOC: Evaluation of a non-endoscopic immunocytological device (Cytosponge™) for post-chemo-radiotherapy surveillance in patients with oesophageal cancer – a feasibility study. Annals of Oncology. 2021 Jul;32:S135–6.